About xCella
xCella is a company based in Menlo Park (United States) founded in 2016 by Bob Chen was acquired by Ligand Pharmaceuticals in September 2020. xCella offers products and services including OmniRat, OmniMouse, OmniChicken, and Omni dAb. xCella operates in a competitive market with competitors including GSK, Avidity Biosciences, PureTech Health, Sutro Biopharma and TScan Therapeutics, among others.
- Headquarter Menlo Park, United States
- Founders Bob Chen
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Omniab, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Ligand Pharmaceuticals
(Sep 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of xCella
xCella offers a comprehensive portfolio of products and services, including OmniRat, OmniMouse, OmniChicken, and Omni dAb.
Transgenic rat platform for human antibody production.
Transgenic mouse system for antibody discovery.
Transgenic chicken host for single-domain antibodies.
Platform for humanized single-domain antibody development.
Funding Insights of xCella
Detailed funding history for xCella
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in xCella
xCella has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Locked | Locked | Locked |
Investor details for xCella
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by xCella
Investment portfolio details for xCella
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - xCella
Detailed financials for xCella
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xcella Comparisons
Peer comparison for xCella
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of xCella
xCella operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, PureTech Health, Sutro Biopharma and TScan Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
Detailed competitors of xCella
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xcella
Complete news archive for xCella
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about xCella
xCella was founded in 2016.
xCella is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
xCella was founded in 2016 and is based in Menlo Park, United States, within the biotechnology sector. Immuno-oncology antibody therapeutics are developed through the proprietary xEmplar human antibody library and xPloration functional screening technology. A pipeline targeting difficult molecules is constructed, with emphasis placed on immunomodulatory agents such as receptor agonists, G-protein coupled receptor modulators, and enzyme inhibitors. Operations center on advancing these therapeutics for oncology applications.
xCella's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
xCella offers OmniRat, OmniMouse, OmniChicken, and Omni dAb.
xCella has 1 investor. Key investors include Ligand Pharmaceuticals.